Core Insights - The company reported total revenue of RMB 358.1 million for the six months ending September 30, 2025, representing an 8.7% year-on-year increase, driven by significant growth in its big data and health management platforms [1] - The company narrowed its losses to RMB 15.8 million, a 72.0% reduction compared to the previous year, while cash flow from operating activities saw a 56.0% year-on-year decrease in net outflow [1] - YiduCore, the company's core algorithm engine, has made significant advancements in developing large language models for the healthcare sector, processing over 13 billion patient records [2] Financial Performance - Total revenue reached RMB 358.1 million, with big data platform revenue increasing by 14.6% and health management platform revenue growing by 30.3% [1] - The company’s loss for the period was reduced to RMB 15.8 million, indicating improved operational efficiency [1] - Cash reserves totaled RMB 2.0993 billion, reflecting a strong liquidity position [1] Technological Advancements - YiduCore has trained its large language model using over 500 billion high-quality tokens and has built a dataset covering more than 98 specific diseases [2] - The company won multiple awards for its medical NLP capabilities, including first place in the healthcare track at the "Data Elements ×" competition [2] Market Engagement - The company provided solutions to 127 top hospitals and 44 regulatory bodies, covering over 10,000 hospitals in total [3] - The number of life sciences clients reached 88, with 17 out of the top 20 multinational pharmaceutical companies as clients [3] - The health management platform has maintained a leading position in core cities, with over 6.15 million insured under the "Shenzhen Hui Min Bao" program [3]

Revenue Performance - For the six months ended September 30, 2025, the total revenue reached RMB 358.1 million, representing an 8.7% year-over-year increase[6]. - Revenue from the big data platform and solutions segment was RMB 153.2 million, up 14.6% compared to RMB 133.7 million in the same period last year[6]. - The health management platform and solutions segment saw a significant growth of 30.3%, with revenue increasing to RMB 66.7 million from RMB 51.2 million[6]. - Revenue for the reporting period reached RMB 138.3 million, a decrease of 4.4% year-on-year[20]. - Revenue increased by 8.7% from RMB 329.4 million for the six months ended September 30, 2024, to RMB 358.1 million for the six months ended September 30, 2025, driven by growth in the big data platform and health management solutions segments[32]. - Revenue from the big data platform and solutions segment rose by 14.6% from RMB 133.7 million to RMB 153.2 million, benefiting from expanded business opportunities due to policy support[32]. - Revenue from the health management platform and solutions segment surged by 30.3% from RMB 51.1 million to RMB 66.6 million, primarily due to changes in the product mix[32]. - Customer contract revenue for the six months ended September 30, 2025, was RMB 358,105 thousand, an increase of 8.3% compared to RMB 329,448 thousand for the same period in 2024[68]. Profitability and Loss - Gross profit for the period was RMB 134.0 million, reflecting a 14.2% increase from RMB 117.4 million in the previous year[6]. - Gross profit increased from RMB 117.4 million to RMB 134.0 million, with gross margin improving from 35.6% to 37.4%[34]. - Operating loss narrowed to RMB 15.7 million, a 71.0% improvement from a loss of RMB 54.3 million in the same period last year[6]. - Period loss reduced by 72.0% from RMB 56.4 million to RMB 15.8 million[41]. - Net loss for the period was RMB 15,760 thousand, a substantial reduction from RMB 56,362 thousand in the previous year[68]. - The company reported a basic and diluted loss per share of RMB 0.01 for the six months ended September 30, 2025, compared to RMB 0.04 in the same period of 2024[69]. Cash Flow and Financial Management - The net cash outflow from operating activities decreased by 56.0% year-over-year, indicating improved cash management[8]. - Cash and cash equivalents decreased from RMB 3,309.1 million to RMB 2,099.3 million as of September 30, 2025[42]. - Other income for the six months was RMB 80,916 thousand, slightly down from RMB 82,937 thousand in 2024[68]. - Total operating expenses, including cost of sales, sales and marketing expenses, administrative expenses, and R&D expenses, amounted to RMB 442,731,000 for the six months ended September 30, 2025, slightly up from RMB 435,455,000 in 2024[84]. User Engagement and Market Reach - The active user base on the health management platform exceeded 22 million, with over 615,000 participants in the "Shenzhen Hui Min Bao" insurance program[10]. - The "Shenzhen Huiminbao" program reached over 6.15 million participants, a historical high, with cumulative claims exceeding 390,000[24]. - Active users on the health management platform exceeded 22 million as of September 30, 2025[27]. Research and Development - The company has focused on breakthroughs in AI model development for the medical vertical, investing in a medical large language model with 70 billion parameters, trained on over 500 billion high-quality tokens[12]. - The AI-driven patient recruitment agent based on medical record understanding has significantly improved the efficiency of clinical trial recommendations and data utilization[14]. - The company has developed a lightweight application model that closely matches the performance of larger parameter models, reducing hardware computational requirements[12]. - The company has established a solid partnership network with key medical institutions and research organizations, enhancing its "AI + Medical Insurance" capabilities[21]. Awards and Recognition - The company has been recognized with industry awards, including first prize in the medical health track at the "Data Element X" competition and the best paper award at the CHIP 2025 conference[13]. Corporate Governance and Future Plans - The company has complied with the corporate governance code as per the Hong Kong Stock Exchange listing rules during the reporting period[55]. - The board of directors does not recommend the distribution of an interim dividend for the six months ended September 30, 2025[67]. - The company has no major investments or capital asset plans for the future as of September 30, 2025[46].

健康管理平台和解决方案（HMPS）新增河北和广州两地"惠民保"业务。 机构：光大证券 研究员：付天姿/王贇 事件：近期公司在AI 医疗创新领域取得多项进展，包括深度参与北京市医疗领域国家人工智能应用中 试基地、中标III 期临床研究项目、新增河北和广州两地"惠民保"业务。 深度参与中试基地建设，以核心技术共筑AI 医疗创新高地。9 月12 日，公司作为北京市医疗领域国家 人工智能应用中试基地的核心生态伙伴，深度参与平台建设与场景创新，推动多项标杆项目落地：开发 区域级受试者招募AI智能体，全面提升受试者招募效率与精准度，解决临床研究受试者招募难、招募 慢的核心痛点，已在6 个项目中落地验证；开发北京市AI 应用插件程序，以统一入口方式整合集成多 AI 应用，大幅减轻医疗机构用户操作和系统集成负担。2025 年8 月，国务院发布《关于深入实施"人工 智能+"行动的意见》，文件指出，要优化应用发展环境，布局建设一批国家人工智能应用中试基地。 而后，上海、北京、广州、浙江相继宣布启动医疗领域国家人工智能应用中试基地，我们认为公司基于 医疗大模型技术将深度受益。 生命科学解决方案（LSS）中标III 期临床研究项目， ...

Core Insights - China's pharmaceutical innovation capabilities are gaining global recognition, as highlighted by reports from McKinsey and BCG, which affirm the rise of innovative drugs in various fields and acknowledge the innovation quality of the domestic pharmaceutical industry [1][21][24] - The "Fierce 15" list, published by Fierce Biotech, identifies 15 innovative biotech companies, many of which have corresponding domestic counterparts, indicating the forward-looking nature of China's innovation [1][18] Group 1: AI in Drug Development - AI is becoming a crucial innovation point in drug development, with four companies in the "Fierce 15" list utilizing AI in their drug discovery processes [5][17] - Character Biosciences, established in 2019, leverages vast insurance data to develop drugs for age-related chronic diseases, utilizing AI to create a drug development platform focused on age-related macular degeneration (AMD) [5][7] - The company has raised approximately $230 million, including investments from major players like Bausch + Lomb and Sanofi [5] Group 2: Domestic AI Drug Discovery Companies - Shanghai Drug Farm, founded in 2015, focuses on discovering new drug targets using genetics and AI, with two AI platforms that have identified over 20 innovative targets [8][10] - MoleculeAI, a domestic company, is pioneering AI-driven protein design, aiming to create new proteins on demand, which could represent a new foundation for the bio-economy [14] - Domestic companies are increasingly adopting AI to optimize clinical trial processes, with examples like Deep Intelligence and WuXi AppTec enhancing efficiency through AI tools [16] Group 3: Global Recognition of Chinese Innovation - The "Fierce 15" list includes Chinese companies like Ouro Medicines and Verdiva Bio, showcasing the global reach of Chinese innovation [18][19] - BCG's report indicates that China is becoming a key growth engine in global new modalities, with over 4,000 clinical projects, ranking second globally [21] - McKinsey's analysis highlights a fundamental change in China's position in the global innovative drug industry, predicting that by 2030, China will account for 10% to 15% of new drug listings globally [24][23]

| 总量研究 2 | | --- | | 上周观点 2 | | 重点报告 2 | | 行业研究 4 | | 上周观点 4 | | 重点报告 5 | | 公司研究 6 | | 重点报告 6 | | 重点报告摘要 7 | | 总量研究 7 | | 行业研究 9 | | 公司研究 11 | 一周观点 总量研究 上周观点 | 领域 | 一周观点 | 分析师 | | --- | --- | --- | | | 市场大方向或仍处在牛市中，不过短期或进入宽幅震荡阶段。与往年牛市相比，当前指数仍然 | | | 策略 | 有相当大的上涨空间，但是在国家对于"慢牛"的政策指引之下，牛市持续的时间或许要比涨 | 张宇生 | | | 幅更加重要。不过短期来看，市场可能缺乏强力催化，叠加年末部分投资者在行为上可能趋于 | | | | 稳健，股市短期或以震荡蓄势为主。 | | | | 上周黄金价格上涨，国内权益市场指数集体回调,医药主题基金表现占优，TMT 主题基金回撤 | | | 金工 | 明显。不同投资范围的 ETF 资金均呈现流入，TMT、科创主题 ETF 受被动资金加仓，以恒生 | 祁嫣然 | | | 互联网 ETF 为代表的港 ...

Core Viewpoint - The report by Everbright Securities highlights significant advancements made by Yidu Tech (医渡科技) in the field of AI healthcare, establishing a preliminary "data-algorithm-scenario" closed-loop model that accelerates business implementation across multiple scenarios [1] Group 1: AI Healthcare Innovations - Yidu Tech is deeply involved in the construction of the national AI application pilot base in Beijing, serving as a core ecological partner and driving the implementation of several benchmark projects [1] - The company has developed an "AI recruitment agent" for clinical trial participants, which has been validated in six projects, significantly improving the efficiency and accuracy of participant recruitment [1] - Yidu Tech has also created an AI application plugin for Beijing, integrating various AI tools to reduce the operational and system integration burden on medical institutions [1] Group 2: Clinical Research Projects - In September, Yidu Tech announced winning a bid for the Phase III clinical research project of recombinant human nerve growth factor (SMR001) eye drops, with a total amount of approximately 55.82 million RMB [2] - The company leverages its medical large model to efficiently produce high-quality clinical evidence and disease knowledge graphs, addressing the pain points of long duration, high costs, and low success rates in clinical trials [2] - With a continuously expanding high-quality client base, Yidu Tech is expected to further enhance its market share in the medium to long term [2] Group 3: Health Management Platform - Yidu Tech has recently launched "Hui Min Bao" insurance services in Hebei and Guangzhou, contributing intelligent services to these initiatives [3] - The company has participated in "Hui Min Bao" projects across 5 provinces and 13 cities, serving over 40 million insured users [3] - Utilizing intelligent models and risk prediction capabilities, Yidu Tech provides comprehensive solutions from product design to operational services for urban inclusive insurance, with expectations for continued penetration into high-tier cities [3] Group 4: Investment Outlook - Everbright Securities maintains a "buy" rating for Yidu Tech, expressing optimism about the company's ongoing innovations and ability to implement AI healthcare solutions [3]

智通财经APP获悉，光大证券发布研报称，考虑到公司在AI医疗创新领域取得多项进展，维持医渡科技 (02158)"买入"评级，近期公司在AI医疗创新领域取得多项进展，包括深度参与北京市医疗领域国家人 工智能应用中试基地、中标III期临床研究项目、新增河北和广州两地"惠民保"业务。 风险提示 深度参与中试基地建设，以核心技术共筑AI医疗创新高地 医疗数字化推进不及预期、医疗数字化行业竞争加剧、生命科学解决方案及健康管理平台和解决方案分 部商业化推进不及预期。 9月12日，公司作为北京市医疗领域国家人工智能应用中试基地的核心生态伙伴，深度参与平台建设与 场景创新，推动多项标杆项目落地：开发区域级受试者招募AI智能体，全面提升受试者招募效率与精 准度，解决临床研究受试者招募难、招募慢的核心痛点，已在6个项目中落地验证;开发北京市AI应用插 件程序，以统一入口方式整合集成多AI应用，大幅减轻医疗机构用户操作和系统集成负担。2025年8 月，国务院发布《关于深入实施"人工智能+"行动的意见》，文件指出，要优化应用发展环境，布局建 设一批国家人工智能应用中试基地。而后，上海、北京、广州、浙江相继宣布启动医疗领域国家人工智 ...

Core Insights - The report suggests that the current market position may be the starting point of a long-term bull market, supported by gradual improvements in fundamentals and industry highlights [3][4] - The report emphasizes the importance of time over space in the current bull market, indicating that the duration of the bull market may be more significant than the magnitude of the increase [3][4] Industry Research Construction Materials - The investment strategy focuses on three main lines: 1) Real estate chain recovery, emphasizing resilient consumer building material leaders like Dongfang Yuhong and Beixin Building Materials, which are expected to have greater profit elasticity amid rising demand for stock updates 2) Overseas growth, targeting companies with established advantages and mature operations abroad, such as Huaxin Cement and Conch Cement 3) Corporate transformation, highlighting construction companies actively restructuring and innovating during industry downturns, like Shanghai Port and Hongrun Construction [10] Machinery Manufacturing - The investment strategy revolves around three major themes: 1) Cycle recovery in engineering machinery, with internationalization, electrification, and intelligentization opening new growth spaces 2) Data center power generation equipment, driven by increased electricity demand 3) Nuclear fusion, entering a phase of capital expenditure expansion with high technical barriers [11] Company Research Aidi Precision (603638.SH) - Aidi Precision reported revenue of 2.37 billion yuan for Q1-Q3 2025, a year-on-year increase of 16.5%, and a net profit of 320 million yuan, up 12.6% year-on-year - The company is expected to benefit from the recovery in the engineering machinery sector, with continued growth in demand for its hydraulic components and new products like industrial robots and RV reducers [12] NetEase-S (9999.HK) - NetEase's Q3 2025 game revenue fell short of expectations due to the deferral of income recognition - The company maintains revenue forecasts of 114.5 billion yuan for 2025, 123.6 billion yuan for 2026, and 132.2 billion yuan for 2027, with a focus on new game releases expected to contribute significantly in 2026 [13] Yidu Technology (2158.HK) - Yidu Technology has made progress in AI medical innovation, but revenue forecasts for FY26 and FY27 have been reduced by 19.4% and 24.9% respectively - The company is expected to achieve a net profit of 0.08 billion yuan in FY28, maintaining a "buy" rating despite the adjustments [14] NVIDIA (NVDA.O) - NVIDIA's FY26 Q3 performance exceeded market expectations, with a projected GAAP net profit of $113.88 billion for FY2026 - The company has raised its FY2027-2028 net profit forecasts by 14.1% and 14.7%, driven by strong demand for AI computing [15] Lenovo Group (0992.HK) - Lenovo reported revenue of $20.452 billion for FY26 Q2, a 15% year-on-year increase, with adjusted net profit rising 25% - AI-related business revenue accounted for 30% of total revenue, up 13 percentage points year-on-year, despite downward adjustments in profit forecasts for FY26 to FY28 [16]

Market Overview - The market is currently in a bull phase, but may enter a wide fluctuation stage in the short term. Compared to previous bull markets, there is still significant room for index growth, but the duration of the bull market may be more important than the magnitude of the increase due to government guidance on a "slow bull" policy. In the short term, the market may lack strong catalysts, and investors may adopt a more cautious approach as the year-end approaches, leading to a focus on consolidation and accumulation [4]. Short-term Opportunities - The market has shifted from previous range-bound fluctuations to a continuous decline influenced by overseas trading sentiment. The artificial intelligence sector continues to adjust, while sectors like chemicals, non-ferrous metals, and electric equipment have seen significant corrections. There may be short-term rebound opportunities in oversold sectors, but the overall market is expected to continue wide fluctuations. The main strategy during this phase should focus on dividend allocation [5]. Fixed Income Market - The convertible bond market and equity market both experienced declines this week. Since the beginning of 2025, both markets have been on an upward trend. Currently, the remaining duration of existing convertible bonds is shortening, and the number of quality individual bonds is decreasing. High-priced and overvalued convertible bonds may face adjustment pressure, making trading more challenging. It is recommended to assess bonds based on their terms and underlying stock conditions, and to pay attention to new bond opportunities in high-demand industries [6]. Oil and Gas Sector - The international oil price is under pressure due to supply-demand imbalances, but OPEC+ has paused production increases, which may alleviate the global oversupply situation. The resilience of the "three major oil companies" during the oil price downturn highlights their ability to navigate through cycles. With expectations of a cold winter, there is potential for significant growth in natural gas demand, making the natural gas business of the "three major oil companies" particularly valuable [8]. Chemical Industry - The organic silicon industry is expected to improve due to the implementation of decisions made at industry conferences, which may enhance the competitive landscape. Recent trends in organic silicon prices and profitability indicate this improvement. In the medium to long term, steady growth in apparent consumption will support demand, while a slowdown in new capacity additions will ease supply pressures, leading to a more favorable industry outlook [8]. AI Healthcare Sector - Medical technology company achieved a revenue of 4.05 billion RMB for FY26H1, representing a year-on-year increase of 33%. The gross profit was 1.44 billion RMB, with a gross margin of 35.7%, down 7.4 percentage points year-on-year. Adjusted EBITA was 550 million RMB, showing a 14% increase compared to the previous year after excluding one-time gains. The net profit attributable to shareholders was 520 million RMB, up 54% year-on-year [9]. Lenovo Group - Lenovo reported a revenue of 20.452 billion USD for FY26Q2, a 15% year-on-year increase. The adjusted net profit attributable to shareholders was 512 million USD, up 25% year-on-year. All business segments achieved double-digit growth, with AI-related business revenue accounting for 30% of total revenue, an increase of 13 percentage points year-on-year [9].

点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 事件： 近期公司在AI医疗创新领域取得多项进展，包括深度参与北京市医疗领域国家人工智能应用中试基地、中标 III期临床研究项目、新增河北和广州两地"惠民保"业务。 深度参与中试基地建设，以核心技术共筑AI医疗创新高地 9月12日，公司作为北京市医疗领域国家人工智能应用中试基地的核心生态伙伴，深度参与平台建设与场景创 新，推动多项标杆项目落地：开发区域级受试者招募AI智能体，全面提升受试者招募效率与精准度，解决临 床研究受试者招募难、招募慢的核心痛点，已在6个项目中落地验证；开发北京市AI应用插件程序，以统一入 口方式整合集成多AI应用，大幅减轻医疗机构用户操作和系统集成负担。2025年8月，国务院发布《关于深入 实施"人工智能 ...